Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 9/20 | 0.46 |
| ▸ | MAPK9 | P45984 | 6/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 4/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.42 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
| ▸ | GSK3A | P49840 | 2/20 | 0.40 |
| ▸ | GSK3B | P49841 | 2/20 | 0.40 |
| ▸ | JUN | P05412 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10323449 | 0.76 | DYRK1A (0.43) | — | |
| SCHEMBL16802771 | 0.76 | MAPK8 (0.66) | MAPK8MAPK9MAPK10MAPK14RIPK2 | |
| SCHEMBL17910207 | 0.76 | MAPK8 (0.66) | MAPK8MAPK9MAPK10MAPK14RIPK2 | |
| SCHEMBL30892313 | 0.76 | MAPK8 (0.65) | MAPK8MAPK9GSK3AGSK3B | |
| SCHEMBL31532080 | 0.76 | MAPK14 (0.47) | MAPK8MAPK9MAPK10MAPK14GSK3B | |
| SCHEMBL14391661 | 0.71 | MAPK8 (0.57) | MAPK8MAPK9MAPK10MAPK14RIPK2 | |
| SCHEMBL10322403 | 0.71 | KDM4E (0.47) | — | |
| SCHEMBL558518 | 0.71 | CSNK2A1 (0.58) | MAPK8MAPK9MAPK10 | |
| SCHEMBL558517 | 0.71 | CSNK2A1 (0.58) | MAPK8MAPK9MAPK10 | |
| SCHEMBL30693042 | 0.70 | HCAR3 (0.57) | MAPK8MAPK9MAPK10ADORA1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012098065-A1 | PYRIDO PYRIMIDINES FOR USE AS DYRK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | WO | claimed |
| US-20120184542-A1 | PYRIDO PYRIMIDINES | ANDERSON KEVIN (US) | 2012-07-19 | — | — | US | claimed |
| WO-2012098065-A1 | PYRIDO PYRIMIDINES FOR USE AS DYRK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | WO | disclosed |
| US-20120184542-A1 | PYRIDO PYRIMIDINES | ANDERSON KEVIN (US) | 2012-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184542-A1 | PYRIDO PYRIMIDINES | TYMS, TYMP, DPYD | MAPK8 2282/4885MAPK9 1565/4885MAPK10 1866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.